Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
Its latest fundraising round provides the French biotech with enough cash to finance operations through 2029.
Read the full story at Europe News →EUROS aggregates the world's financial press. The full article lives with the newsroom that reported it.